Basel, Switzerland, 16th July 2009 - Evolva SA, a Swiss headquartered international biotech company focused on the discovery and development of drugs based on its genetic chemistry platform, today announced it has completed a single ascending dose Phase I clinical trial in healthy volunteers with EV-077-3201-2TBS.
The study in 56 healthy male volunteers was conducted over 12 weeks in Germany. The single ascending dose study showed that EV-077-3201-2TBS achieved good exposure levels, was well tolerated, fast acting and reversible and showed clinically relevant pharmacodynamic effects. Based on these results, Evolva will next conduct the multiple ascending dose stage of the Phase I study.
Dr. Alexandra Santana Sorensen, VP R&D of Evolva said: “We are very pleased with the results of the Phase I single ascending dose study on EV-077, which are very much in-line with the predictions from the pre-clinical studies. Our first drug candidate has been demonstrated to be highly potent, safe and orally available with characteristics that suggest it should have important advantages compared to existing drugs.”
EV-077-3201-2TBS is a new chemical entity, with a different mode of action from existing drugs, that is being developed for renal and cardiovascular indications, in particular proteinuric kidney diseases and anti-platelet indications.
Evolva uses its genetic chemistry platform to replicate, on an industrial basis, the ability of nature to create small molecules with exquisite “design”. Based on this technology, Evolva has a number of third party discovery and pre-clinical programs. Evolva’s drug development activities focus on cardiovascular, renal and infectious diseases. Evolva had revenues of about CHF 10 million in 2008.
For more information see www.evolva.com.
Alexandra Santana Sorensen
Phone: +41 61 485 20 20
Fax: +41 61 485 20 01